139 trends tracked about this subject — the full history, oldest to newest below.
Internal medicine physician Dr. Frank Dumont warns that stopping GLP-1 medications like Ozempic and Zepbound carries six rebound risks, including rapid weight regain, loss of cardiovascular protection, and worsening mental health.
The FDA warns that widely used GLP-1 medications like Ozempic and Zepbound carry a potential risk of vision loss.
Federal regulators mandate new vision loss warning labels across the widely used GLP-1 receptor agonist drug class.
Federal regulators issue a new warning regarding GLP-1 medications and a rare eye condition linked to sudden blindness.
The FDA is requiring all GLP-1 drug makers to add a warning about NAION, a rare eye condition that can cause sudden blindness, to their prescribing information.
A small Adelaide University sheep study found a single dose of semaglutide cut maternal cardiac output and fetal oxygen levels within two hours, raising new questions about GLP-1 drug safety during pregnancy.
A 40-week study found that resistance training helped people taking tirzepatide lose 25% less lean tissue while improving strength by 10%.
Recent reporting examines the challenges of weight maintenance and patient adherence after stopping GLP-1 medications.
Novo Nordisk raises its 2026 outlook and shares surge as the Wegovy weight-loss pill rollout accelerates.
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Eli Lilly reports that its new drug, retatrutide, achieved more than double the weight loss of Ozempic's highest approved dose in a head-to-head trial.
Recent studies link popular GLP-1 weight-loss drugs to unexpected dermatological side effects like nail detachment and hair loss.
3 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Recent coverage links GLP-1 medications like Ozempic and Wegovy to legal action involving vision loss alongside contrasting studies.
A growing wave of coverage examines newly reported links between popular GLP-1 medications and rare instances of severe vision loss.
Recent reporting examines whether GLP-1 weight-loss medications could help women conceive and boost fertility outcomes.
Popular weight loss medications face new scrutiny as coverage connects them to unusual nail and hair complications.
Recent studies indicate that popular GLP-1 weight-loss medications like Ozempic and Mounjaro may also slow biological aging.
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
3 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Recent coverage examines the phenomenon of 'Ozempic babies' and the broader relationship between GLP-1 drugs and women's health.
10 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
1 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Recent studies link popular GLP-1 weight-loss drugs to surprising physical side effects including hair loss and nail troubles.
2 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
7 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Recent studies link weight-loss medications like Ozempic and Wegovy to unexpected hair and nail side effects.
A Massachusetts man's lawsuit alleging permanent blindness from Ozempic highlights growing legal and medical concerns over GLP-1 weight loss drugs.
7 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
2 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
1 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
McDonald's is reshaping its menu offerings to adapt to changing consumer habits and the rise of GLP-1 weight-loss drugs.
Over one million Americans are now taking GLP-1 medications without a documented diagnosis of diabetes or obesity, according to recent reports.
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
GLP-1 users express intense anger as employers begin dropping insurance benefits for the sought-after medications.
Prescriptions for GLP-1 drugs like Ozempic among Americans without medical needs are surging across multiple demographic groups.
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
New reports warn that discontinuing GLP-1 weight-loss medications like Ozempic, Mounjaro, and Wegovy may increase the risk of heart attack and stroke.
Major drugmakers Novo Nordisk and Eli Lilly face numerous lawsuits alleging popular GLP-1 medications cause sudden vision loss.
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
2 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
4 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
A large genetic study connects GLP-1 receptor activation to improved mental well-being.
7 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Recent coverage examines rapid weight regain after discontinuing GLP-1 medications like Ozempic, semaglutide, and tirzepatide.
GLP-1 medications face growing attention for unexpected health benefits and wider usage trends beyond weight management.
Medical experts and journalists are working to distinguish scientific facts from social media hype regarding side effects of GLP-1 weight loss medications.
New research indicates that GLP-1 medications like Ozempic and Wegovy may significantly reduce the frequency of asthma attacks and COPD flare-ups.
A new observational study links weight regain following the use of obesity medications to an increased risk of suicidal thoughts.
Growing concerns emerge over the 'Ozempidemic' as users report intense cravings and safety risks associated with GLP-1 weight-loss medications.
New reports suggest popular GLP‑1 weight‑loss drugs may trigger male pattern baldness, sparking medical and public‑interest scrutiny.
2 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Recent studies indicate that GLP-1 weight loss medications may worsen or accelerate hair loss in men.
A growing cultural and medical debate is emerging over the use of GLP-1 medications, focusing on the tension between clinical benefits and social stigma.